As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in patients with advanced solid tumors. IMA401 is a so-called bispecific T-cell engager (TCER) that specifically links cancer cells with T cells, thereby directly activating the immune system to fight the tumor. To achieve this, the molecule simultaneously binds to two targets: a protein produced in tumor cells known as the tumor antigen MAGEA4/8, and a molecule on the surface of the body's immune cells (CD3). These immune cells, known as T lymphocytes, are thereby directed specifically to the tumor locations and activated so that they can destroy the cancer cells.

A study led by researchers from the Respiratory and Immune Repair (REPAIR) group at the Germans Trias i Pujol Research Institute (IGTP), in collaboration with researcher Daniel Closa from IIBB-CSIC, Enrique de-Madaria from ISABIAL and CIBEREHD, and researcher Karina Cárdenas-Jaen from Miguel Hernández University, has identified alterations in the endocannabinoid system associated with the most severe forms of acute pancreatitis.

When most humans reach late adulthood, their ability to coordinate movements and maintain balance, broadly referred to as motor control, tends to gradually decline. While these changes in motor control are widely documented, the extent to which they also affect sensorimotor learning (i.e., the adaptation of movements based on information from the environment) remains unclear.

Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, potentially sparing them unnecessary side effects without increasing the risk of the cancer returning, a large international clinical trial led by UCL has found.

In a new study published in JAMA, the diagnostic yield of transbronchial lung biopsy was significantly higher when using a cryoprobe versus forceps in a group of patients with pulmonary nodules or masses, recent lung transplant, and diffuse parenchymal lung disease.

Moments after Jenna Carberg gave birth to her daughter, doctors put the baby on her chest.

Higher-dose ocrelizumab produced greater peripheral B-cell depletion than the approved 600 mg regimen in two phase 3b trials of relapsing and primary progressive multiple sclerosis. However, the higher doses did not significantly delay disability progression, supporting the 600 mg dose as the current standard regimen with a favorable benefit-risk profile.

A new type of peptide receptor radionuclide therapy (PRRT) appears to be safe in metastatic neuroendocrine tumor patients who have exhausted conventional treatment options.

The Lancet World Report examines why regulators in the US, UK, and Europe have reached different decisions on new amyloid-targeting Alzheimer’s drugs despite evidence that they can modestly slow clinical decline. It highlights the unresolved balance among benefits, safety risks, costs, access, and the need for broader, earlier, and more patient-centered treatment strategies.

A first-in-class PET imaging approach can accurately detect a biomarker for chronic traumatic encephalopathy (CTE), a devastating neurodegenerative disease associated with repeated head impact.